Good MorningEquity markets pulled back for Wednesday's 3rd day this week as a growing fear of an economic downturn saps bullish sentiment. The downturn, which has been expected for several quarters, appears to be finally here based on guidance from retailers like Target and Lowe's. In their view, consumer spending will fall double-digit this year, on top of a 30% correction in the housing market—demand for mtg fells to a 28-year low and points to a deepening correction in that sector.
On the bright side, not all is lost in the investing world. While most of the S&P 500 index is under pressure, some sectors, like fast food, are producing growth and guiding for growth in 2023. These stocks offer investors a range of opportunities, including blue chip safety, high yield, and value, depending on where you look. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Industrials | |
Plug Power’s (NASDAQ: PLUG) Q4 and FY results have the shares moving sharply lower, but this is a knee-jerk reaction to headline news. The results were weaker than expected but should not have been a surprise given the early phase of the business. Start-ups across sectors, industries, and ve... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Consumer Discretionary | |
Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) are down more than 17% the day after the company delivered a disappointing earnings report. The results were mixed and not altogether poor, but they were still enough to give investors a taste of consumers' anxiety about electric vehicles.
Rivian ... Read the Full Story |
|
Consumer Staples | |
Target Corporation’s (NYSE: TGT) shares were down more than 4% in Wednesday’s session, despite the retailer beating the headline expectations in their earnings report yesterday. As initial reactions go to quarterly updates, you’d be forgiven for thinking it was an odd one, but on... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
A high dividend yield can be an attractive feature, as it’s a way of gauging a stock’s dividend payout relative to its price. Some of the highest yields can be found in oil-and-gas master limited partnerships and tanker companies, but you can also get high yields from many other sector... Read the Full Story |
|
Consumer Discretionary | |
Jack in the Box (NASDAQ: JACK) CEO Darrin Harris has this company wound up and ready to spring into growth. He has been rationalizing operations across the system, focusing on building the franchise network and growing into new markets. His efforts include menu choices and standardizations, a push... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
If you are wondering how low Lowe’s Companies (NYSE: LOW), or Home Depot (NYSE: HD), can go, the answer is a lot lower. The charts are set up to suggest a generational-quality pullback is underway in these blue-chip dividend payers, which is good news for long-term investors. Current stockho... Read the Full Story |
|
Technology | |
Ambarella (NASDAQ: AMBA) has had its share of ups and downs, but it has always come out of its slumps in a better position than before. Today’s issues are inventory-related, with the Q4 results and 2023 outlook at less-than-expected levels. The takeaway from the report is that inventory leve... Read the Full Story |
|
Consumer Discretionary | |
Wendy’s (NASDAQ: WEN) and McDonald’s (NYSE: MCD) are not the same sizes but on equal footing in many ways. Both companies produce double-digit growth, trade about 25X their earnings, and pay relatively safe and attractive dividends. The difference is that Wendy’s produced double-... Read the Full Story |
|
Markets | |
Terran Orbital Co. (NYSE: LLAP) makes and operates small satellites for the defense and aerospace industries. Its stock spiked over 80% on the news of being awarded a $2.4 billion contract. Its wholly owned subsidiary Tyvak Nano-Satellite Systems received $2.4 billion from Rivada Space Networks to... Read the Full Story |
|
Consumer Staples | |
In a down month for U.S. equities, General Mills, Inc. (NYSE:GIS) bucked the tide in February 2023. It’s something the packaged foods maker has grown quite accustomed to.
In 2022, when the S&P 500 suffered its worst year since 2008, General Mills ran 24%. Part of it was investors seekin... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
